View Document Preview and Link Document Date: 2014-11-06 23:49:39 Open Document File Size: 348,58 KB Share Result on Facebook
Company AEs / BOTOX / Allergan Australia Pty Ltd / Consumer Impact Statement There / MSAC / PBS / Total services / / Country Australia / / Currency USD / / Event Funding / / IndustryTerm injection site / health services / clinical management / conservative management / inpatient services / placebo / agreed clinical protocols / health insurance / utility weights using accepted scoring algorithms / literature search / health technology assessments / / MarketIndex MBS / / MedicalCondition primary neurologic disorder / urinary retention / urge incontinence / urinary incontinence / urinary tract infection / Parkinson's disease / neurologic disorder / multiple sclerosis / urinary tract infections / non-neurologic disease / urinary incontinence Pre- anaesthesia / MS / idiopathic overactive bladder / spinal cord injury / spina bifida / Bladder infection / disease / stroke / overactive bladder syndrome / Pain / Parkinson’s disease / defined neurological illness / / MedicalTreatment antibiotics / retreatment / clinical protocols / / Organization Pharmaceutical Benefits Advisory Committee / Workers’ Compensation Regulatory Authority / Medicare / Australian Medical Association / Australian Health Ministers’ Advisory Council / Medical Services Advisory Committee / / Position Minister / anaesthetist / Governor / Executive / / Product Intravesical injection / Botox injection / / ProvinceOrState Mississippi / / Technology agreed clinical protocols / / URL www.msac.gov.au / / SocialTag 
Public Summary Document Application 1221 – Intravesical injection of BOTOX® (botulinum toxin type A) for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) Sponsor/Applicant/s: Aller